secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2026-01-13T23:59:59+00:00
Accession:  0001193125-26-011177
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q4 2025 preliminary revenue falls ~9% YoY; full year in line with guidance
--------------------------------------------------------------------------------

- Q4 2025 revenue $62.1M-$62.5M, down ~9% YoY at midpoint.
- Full-year 2025 revenue $212.3M-$212.7M, ~2% YoY growth, in line with $211M-$213M guidance.
- Added ~202 new active surgeons in 2025; total active surgeons ~3,337 (+6%).
- Not issuing FY 2026 guidance now; will provide during Q4 earnings call on Feb 26, 2026.
- CEO cites headwinds from broader economic conditions, softer consumer sentiment, product mix shift.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000119312526011177/0001193125-26-011177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000119312526011177/tmci-20260113.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-011177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer